Article Text

Download PDFPDF
  1. Rob McMurray1,
  2. Camilla Karlsson2,
  3. Rui Sousa3,
  4. Martin Holtkamp4
  1. 1 Eisai Europe Ltd
  2. 2 Eisai AB Stockholm
  3. 3 Bial, Portugal
  4. 4 Charité - Universitätsmedizin Berlin, Germany


Purpose To assess eslicarbazepine acetate (ESL) in patients included in the Eslicarbazepine acetate in Partial-Onset Seizures (EPOS) study who had previously not responded to carbamazepine (CBZ) treatment.

Method EPOS was a prospective, non-interventional study, conducted under everyday clinical practice conditions in adult patients with uncontrolled partial-onset seizures receiving antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy. A post hoc analysis was conducted in those with a documented non-response to historic CBZ treatment. Assessments included retention, responder and seizure freedom rates, Quality of Life in Epilepsy Inventory-10 (QOLIE-10) score, and safety/tolerability.

Results Forty-five patients had documented non-response to CBZ. Two patients discontinued ESL due to AEs and one due to lack of efficacy. After 6 months, retention, responder and seizure freedom rates (with 95% confidence intervals) were 88.9% (75.9–96.3%; n=45), 95.1% (83.5–99.4%; n=41) and 33.3% (19.6–49.5%; n=42), respectively. Mean QOLIE-10 total score decreased from 2.8 (n=21) at baseline to 2.2 (−13.0%; n=18) after 6 months. Two adverse events were reported for two patients (both hyponatremia).

Conclusion ESL was effective and well tolerated as add-on to antiepileptic monotherapy in patients with documented non-response to CBZ treatment in a real-world setting.

Supported by Eisai.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.